These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 6236186

  • 1. Pharmacokinetics and toxicology of continuously infused nitroimidazoles.
    Eifel PJ, Brown JM.
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1311-4. PubMed ID: 6236186
    [Abstract] [Full Text] [Related]

  • 2. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
    Coleman CN, Halsey J, Cox RS, Hirst VK, Blaschke T, Howes AE, Wasserman TH, Urtasun RC, Pajak T, Hancock S.
    Cancer Res; 1987 Jan 01; 47(1):319-22. PubMed ID: 3024818
    [Abstract] [Full Text] [Related]

  • 3. Sensitization of normal and malignant tissue to cyclophosphamide by nitroimidazoles with different partition coefficients.
    Hirst DG, Hazlehurst JL, Brown JM.
    Br J Cancer; 1984 Jan 01; 49(1):33-42. PubMed ID: 6229264
    [Abstract] [Full Text] [Related]

  • 4. Clinical trials of radiosensitizers: what should we expect?
    Brown JM.
    Int J Radiat Oncol Biol Phys; 1984 Mar 01; 10(3):425-9. PubMed ID: 6231272
    [Abstract] [Full Text] [Related]

  • 5. Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations.
    Wong KH, Wallen CA, Wheeler KT.
    Int J Radiat Oncol Biol Phys; 1990 May 01; 18(5):1043-50. PubMed ID: 2140824
    [Abstract] [Full Text] [Related]

  • 6. KIH-802, an acetohydroxamic acid derivative of 2-nitroimidazole, as a new potent hypoxic cell radiosensitizer: radiosensitizing activity, acute toxicity, and pharmacokinetics.
    Sasai K, Shibamoto Y, Takahashi M, Zhou L, Hori H, Nagasawa H, Shibata T, Inayama S, Abe M.
    Cancer Chemother Pharmacol; 1990 May 01; 26(2):112-6. PubMed ID: 2140730
    [Abstract] [Full Text] [Related]

  • 7. [Recent advances in hypoxic cell radiosensitizer].
    Ono K, Takahashi M, Nishidai T, Shibamoto Y, Abe M.
    Gan No Rinsho; 1983 Oct 01; 29(13):1608-12. PubMed ID: 6230470
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
    Coleman CN, Urtasun RC, Wasserman TH, Hancock S, Harris JW, Halsey J, Hirst VK.
    Int J Radiat Oncol Biol Phys; 1984 Sep 01; 10(9):1749-53. PubMed ID: 6237086
    [Abstract] [Full Text] [Related]

  • 10. Response of murine tumours to combinations of CCNU with misonidazole and other radiation sensitizers.
    Siemann DW.
    Br J Cancer; 1982 Feb 01; 45(2):272-81. PubMed ID: 6460517
    [Abstract] [Full Text] [Related]

  • 11. A new, potent 2-nitroimidazole nucleoside hypoxic cell radiosensitizer, RP170.
    Sasai K, Shibamoto Y, Takahashi M, Abe M, Wang J, Zhou L, Nishimoto S, Kagiya T.
    Jpn J Cancer Res; 1989 Nov 01; 80(11):1113-8. PubMed ID: 2532634
    [Abstract] [Full Text] [Related]

  • 12. The concentration of desmethylmisonidazole in human tumours and in cerebrospinal fluid.
    Dische S, Saunders MI, Riley PJ, Hauck J, Bennett MH, Stratford MR, Minchinton AI.
    Br J Cancer; 1981 Mar 01; 43(3):344-9. PubMed ID: 7225285
    [Abstract] [Full Text] [Related]

  • 13. Radiosensitizing activity and pharmacokinetics of multiple dose administered KU-2285 in peripheral nerve tissue in mice.
    Iwai H, Matsuno E, Sasai K, Shibamoto Y, Abe M.
    Int J Radiat Oncol Biol Phys; 1994 Jun 15; 29(3):591-4. PubMed ID: 8005821
    [Abstract] [Full Text] [Related]

  • 14. The clinical testing of Ro 03-8799--pharmacokinetics, toxicology, tissue and tumor concentrations.
    Saunders MI, Anderson PJ, Bennett MH, Dische S, Minchinton A, Stratford MR, Tothill M.
    Int J Radiat Oncol Biol Phys; 1984 Sep 15; 10(9):1759-63. PubMed ID: 6480459
    [Abstract] [Full Text] [Related]

  • 15. Studies in radiosensitizing effects of misonidazole and SR-2508 on C3H/He mouse mammary tumors.
    Ono K, Takahashi M, Nishidai T, Dodo Y, Shibamoto Y, Hiraoka M, Yukawa Y, Abe M.
    Radiat Med; 1984 Sep 15; 2(1):71-5. PubMed ID: 6242712
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508.
    Yu NY, Brown JM.
    Int J Radiat Oncol Biol Phys; 1984 Aug 15; 10(8):1265-9. PubMed ID: 6236185
    [Abstract] [Full Text] [Related]

  • 18. Radiosensitizing, toxicological, and pharmacokinetic properties of hydroxamate analogues of nitroimidazoles as bifunctional radiosensitizers/chemical modifiers.
    Nagasawa H, Bando M, Hori H, Satoh T, Tada T, Onoyama Y, Inayama S.
    Int J Radiat Oncol Biol Phys; 1992 Aug 15; 22(3):561-4. PubMed ID: 1735696
    [Abstract] [Full Text] [Related]

  • 19. Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and Ro 03-8799.
    Dische S, Saunders MI, Dunphy EP, Bennett MH, Des Rochers C, Stratford MR, Minchinton AI, Orchard RA.
    Int J Radiat Oncol Biol Phys; 1986 Jul 15; 12(7):1109-11. PubMed ID: 2943708
    [Abstract] [Full Text] [Related]

  • 20. Interactions of hyperthermia with hypoxic cell sensitisers.
    Bleehen NM, Walton MI, Workman P.
    Recent Results Cancer Res; 1988 Jul 15; 109():136-48. PubMed ID: 2972029
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.